本议案需提交 2025 年第三次临时股东会审议。 证券代码：300261 证券简称：雅本化学 公告编号：2025-059 雅本化学股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）第六届董事会第五次（临时）会议 于 2025 年 8 月 12 日上午 10:00 以现场结合通讯方式召开，会议通知已于 2025 年 8 月 7 日以邮件方式送达全体董事。本次会议应出席董事 8 名，实际出席会议董事 8 名。会议由公司董事长兼总经理蔡彤先生主持，公司部分高级管理人员列席了会议。 本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 一、审议通过了《关于增补公司第六届董事会非独立董事的议案》 为确保公司治理结构的规范运作与完整性，保障董事会决策效率，董事会同意 增补财务总监王爱军先生为公司第六届董事会非独立董事候选人，任期自股东会审 议通过之日起至第六届董事会任期届满之日止。详见中国证监会指定信息披露网站 刊登的公告。本议案 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-060 雅本化学股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据雅本化学股份有限公司（以下简称"公司"）第六届董事会第五次（临 时）会议的决定，公司将于 2025 年 8 月 29 日召开公司 2025 年第三次临时股东 会，现将有关事项通知如下： 一、本次会议的基本情况 议通过，决定召开 2025 年第三次临时股东会，召集程序符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 现场会议时间：2025 年 8 月 29 日（星期五）下午 14:30 网络投票时间：2025 年 8 月 29 日 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 8 月 29 日上午 通过深圳证券交易所互联网系统投票的具体时间为 2025 年 8 月 29 日上午 （1）现场投票：股东本人出席现场会议或通过授权委托书委托他人出席； （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络形式的 ...

Core Viewpoint - The company has nominated Mr. Wang Aijun as a candidate for a non-independent director on the sixth board, aiming to enhance governance structure and decision-making efficiency [1]. Group 1: Board Nomination - Mr. Wang Aijun has been nominated as a non-independent director candidate for the sixth board, with the decision approved in a board meeting held on August 12, 2025 [1]. - His term will last from the date of shareholder meeting approval until the end of the sixth board's term [1]. Group 2: Background of Mr. Wang Aijun - Mr. Wang Aijun holds a master's degree and has extensive experience in finance, having served in various senior financial roles across multiple companies [1]. - He currently holds 10,500 shares directly and 300,000 shares indirectly through an employee stock ownership plan [2]. - His qualifications meet the requirements set by relevant laws and regulations, ensuring compliance with corporate governance standards [2]. Group 3: Compliance and Governance Improvements - Following a public reprimand from the Shenzhen Stock Exchange during his tenure as board secretary, the company has implemented corrective measures to enhance information disclosure practices [3]. - The company has improved its information disclosure system and conducted training for board members and senior management to strengthen compliance awareness [3]. - Mr. Wang has been the financial director since 2018, contributing significantly to the company's strategic planning and financial management [3].

证券代码：300261 证券简称：雅本化学 公告编号：2025-061 雅本化学股份有限公司 附件：王爱军简历 王爱军，男，中国国籍，1970 年生，硕士，无永久境外居留权。历任上海沪江 德勤会计事务所审计主管，英维斯楼宇系统亚太区财务总监，圣戈班高功能塑料亚 太区财务总监，荟才环球企业咨询（北京）有限公司顾问，伟速达（中国）汽车安 全系统有限公司财务副总，雅本化学股份有限公司董事会秘书。现任雅本化学股份 有限公司财务总监。 截止目前，王爱军先生直接持有公司股份 10,500 股，通过 2023 年员工持股计 划间接持有公司股份 300,000 股。王爱军先生与其他持有公司 5%以上股份的股东、 其他董事、高级管理人员不存在关联关系；不存在《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》第 3.2.3 条所规定 的情形；不存在因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国证监会立 案调查而尚未有明确结论的情形；未被中国证监会在证券期货市场违法失信信息公 开查询平台公示或者被人民法院纳入失信被执行人名单。其任职资格符合《中华人 民共和国公司法》《深圳证券交易所 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-059 本议案需提交 2025 年第三次临时股东会审议。 二、审议通过了《关于提请召开 2025 年第三次临时股东会的议案》 经审议，董事会同意于 2025 年 8 月 29 日召开 2025 年第三次临时股东会。详见 中国证监会指定信息披露网站刊登的公告。 雅本化学股份有限公司 第六届董事会第五次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）第六届董事会第五次（临时）会议 于 2025 年 8 月 12 日上午 10:00 以现场结合通讯方式召开，会议通知已于 2025 年 8 月 7 日以邮件方式送达全体董事。本次会议应出席董事 8 名，实际出席会议董事 8 名。会议由公司董事长兼总经理蔡彤先生主持，公司部分高级管理人员列席了会议。 本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 一、审议通过了《关于增补公司第六届董事会非独立董事的议 ...

Group 1: Chemical and Oil Indices Performance - The chemical index and oil index showed overall positive performance, with the chemical raw materials index rising by 1.66% and the chemical machinery index increasing by 6.08%. However, the chemical pharmaceuticals index fell by 1.30% [1] - In the oil sector, the oil processing index increased by 0.67%, the oil extraction index rose by 2.70%, and the oil trading index went up by 2.18% [1] Group 2: International Oil Prices - International crude oil prices declined, with WTI settling at $63.88 per barrel, down 5.12% from August 1, and Brent settling at $66.597 per barrel, down 4.42% [1] Group 3: Petrochemical Products Price Changes - The top five petrochemical products with price increases included liquid chlorine up by 14.98%, coke up by 4.57%, mancozeb up by 4%, coking coal up by 3.55%, and aniline up by 2.82%. The top five products with price decreases included folic acid down by 6%, acrylic acid down by 5.51%, vitamin D3 down by 5.41%, WTI down by 5.12%, and synthetic ammonia down by 4.90% [1] Group 4: Capital Market Performance of Chemical Companies - The top five chemical companies with the highest stock price increases were Kexin New Energy up by 53.05%, Amway Co. up by 51.60%, Xinhang New Materials up by 45.88%, Zhongxin Fluorine Materials up by 35.66%, and Huaxin New Materials up by 25.99%. The top five companies with the largest declines were Lianhua Technology down by 10.41%, Cangzhou Dahua down by 8.80%, Zaiseng Technology down by 8.63%, Yabeng Chemical down by 7.86%, and Xinchao Energy down by 7.21% [2]

Group 1 - The stock price of Yabao Chemical is reported at 7.97 yuan, down 1.73% from the previous trading day, with a trading volume of 331,452 hands and a transaction amount of 264 million yuan [1] - Yabao Chemical's main business includes the research, production, and sales of pesticides and pharmaceutical intermediates, covering a complete product line in the pesticide sector, including insecticides, fungicides, and herbicides [1] - On August 7, data shows that four funds participated in the research activities of Yabao Chemical, ranking fifth among 16 companies surveyed that day [1]

Group 1: Company Strategy and Development - The company implements a "2+X" strategy focusing on innovative pharmaceuticals and agricultural chemicals CDMO business, establishing stable partnerships with leading global companies [2] - The production system is structured around "six cores + two collaborations," enhancing the R&D process from laboratory to commercial production [2][3] - The company aims to create a comprehensive "R&D-production" lifecycle chain to support high-end innovative products [2] Group 2: Agricultural Chemicals Business - The company has established a production capacity of 2,000 tons/year for chlorantraniliprole intermediates at the Nantong base, serving international agricultural clients for over a decade [3] - The Yancheng base has a production line for custom pesticide projects with an annual capacity of 500 tons, expected to start supplying next year [15] - The Lanzhou base has achieved a production capacity of approximately 500 tons/year for innovative pesticide intermediates, with an additional 1,000 tons/year capacity under installation [15] Group 3: Pharmaceutical Business - The company has over 20 years of experience in the pharmaceutical CDMO sector, providing comprehensive solutions from early drug development to commercial production [12] - The Taicang base has a production capacity of 60 tons/year for the raw material Levetiracetam, while the Malta base supports over 20 types of pharmaceutical raw materials [9] - The Lanzhou pilot base has established a production line for antiviral drug intermediates with an annual capacity of 15 tons [9] Group 4: Strategic Partnerships - The collaboration with Heng Rui Medicine exemplifies the company's "big client strategy," focusing on innovative product commercialization [12] - Plans for 2025 include launching 5-10 cooperative products, with at least 10 products planned for 2026 [11] - The partnership has expanded from small-scale experiments to comprehensive strategic cooperation across multiple therapeutic areas [12] Group 5: Future Outlook and Investment - The company is preparing to invest in new projects and expand production capacity, with over 100 acres of land reserved for future pharmaceutical and agricultural projects [9] - The company anticipates a gradual recovery in agricultural business performance as new projects are implemented [16] - Continuous investment in core technologies and service capabilities is expected to drive high-quality development in the pharmaceutical sector [12]

Summary of Yabon's Conference Call Company Overview - **Company**: Yabon Chemical - **Industry**: Pharmaceutical and Agrochemical CDMO (Contract Development and Manufacturing Organization) Key Points and Arguments 1. **Strategic Partnerships**: Yabon is implementing a major client strategy by establishing strategic partnerships with leading global pharmaceutical and agrochemical companies, focusing on innovative intermediates and derivative products in pharmaceuticals and agrochemicals [2][3][6] 2. **Business Development Strategy**: The company has adopted a "2 Plus X" business development strategy, emphasizing innovative pharmaceutical and agrochemical CDMO services, while deepening relationships with top global enterprises [3][6][19] 3. **Production Capacity Recovery**: Following the 2019 Jiangsu incident, Yabon has expanded its production capacity through new bases in Fushun, Xiangyang, and the newly built Lanzhou base, successfully restoring and enhancing production capabilities [2][4][5] 4. **International Market Expansion**: Yabon is actively expanding its international market presence, with some raw materials already being supplied to global markets including Australia, South Korea, and Indonesia, with plans to further penetrate North and South America [4][5] 5. **Core Production Bases**: The company operates six core bases and two cooperative factories, with significant R&D capabilities located in Shanghai and Huzhou, and a newly established pilot base in Lanzhou [3][7][14] 6. **New Projects and Capacity**: Yabon plans to launch new projects in its Yancheng and Lanzhou bases, expecting to add 2,000 tons of intermediates and raw materials by 2025 to meet market demands [3][19][21][22] 7. **Collaboration with Major Clients**: Yabon has established a strategic collaboration with Heng Rui Pharmaceutical, focusing on innovative drug development, with plans to support multiple clinical projects [12][13][18] 8. **Challenges and Responses**: The company faces challenges from declining prices of major projects and the need for new projects to ramp up. Yabon is addressing these by optimizing production line layouts and ensuring efficient capacity utilization [25][26] Additional Important Content 1. **Technological Advancements**: Yabon is investing in synthetic biology, fluid chemistry, and green carbon reduction, enhancing its capabilities to support its CDMO business [2][3][6] 2. **Regulatory Compliance**: The company has established bases that comply with GMP standards, including its Malta facility, which is crucial for serving export-oriented clients [8][14] 3. **Future Development Plans**: Yabon aims to build a smart Mega factory within three years, enhancing its large-scale manufacturing capabilities and cost efficiency [19] 4. **Flexibility in Production**: The Lanzhou base offers flexible production capabilities, allowing for co-line production to meet diverse customer needs effectively [24] 5. **Market Adaptation**: Yabon is adapting to market changes by focusing on high-end intermediates and raw materials, ensuring a robust supply chain through strategic partnerships [9][18] This summary encapsulates the essential insights from Yabon's conference call, highlighting the company's strategic direction, operational advancements, and market positioning within the pharmaceutical and agrochemical sectors.

8月6日，雅本化学连续4个交易日下跌，区间累计跌幅-7.95%。雅本化学股份有限公司(以下称"公司")创建于2003年7月,2010年2月改制成股份有限公司;2011 年9月在深圳证券交易所创业板上市。 财报显示，南方基金旗下南方中证1000ETF为雅本化学前十大股东，今年一季度减持。今年以来收益率16.35%，同类排名712(总2850)。 | 阶段涨幅 | 季度涨幅 | 今年以来合阶段业绩及同类排名 年度涨幅 | | | | | --- | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 近6月 | 今年来 | | 阶段涨幅 | 2.15% | 8.88% | 13.47% | 14.69% | 16.35% | | 同类平均� | -0.99% | 5.81% | 12.35% | 13.40% | 11.61% | | 沪深300 | -0.91% | 3.30% | 8.01% | 7.04% | 4.54% | | 股东标的2 | 2.13% | 8.70% | 12.43% | 13.56% | 15.17% | | 同类排名 3 | 36 ...